OCTOBER 15, 2015 (SAN ANTONIO, TX ) bioAffinity Technologies, a privately held cancer diagnostics company, presented its breakthrough technology for the detection and diagnosis of early-stage lung cancer today at McDermott Will & Emery’s 2015 Pharmaceutical/Medtech Dealmaking Symposium in Chicago. bioAffinity Technologies is one of a select group of eight companies in the healthcare sector invited […]
OCTOBER 7, 2015 (SAN ANTONIO, TX ) bioAffinity Technologies, a privately held cancer diagnostics company, will seat two new members on its Board of Directors at the third-quarter meeting Oct. 26, 2015. Company President and Chief Executive Officer Maria Zannes announced that Myron Holubiak and Barry Frankel are joining the Board. Holubiak previously served as President […]
SEPTEMBER 30, 2015 (SAN ANTONIO, TX ) bioAffinity Technologies, a privately held cancer diagnostics company, today announced the renewal of its research collaboration with The University of Texas Health Science Center at San Antonio to optimize its patented CyPath® test that preferentially binds to cancer cells and causes them to fluoresce red under specific frequencies of […]
SEPTEMBER 23, 2015 (SAN ANTONIO, TX ) bioAffinity Technologies, a privately held cancer diagnostics company, today announced that results from a 128-patient proof-of-concept clinical study for its non-invasive and quantitative assay for early-stage lung cancer were published in the September 2015 issue of the Journal of Thoracic Oncology. Study results show the patented CyPath® test was […]